588 related articles for article (PubMed ID: 27461436)
41. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S45-54. PubMed ID: 27183525
[TBL] [Abstract][Full Text] [Related]
42. The Role of Multimodality Cardiac Imaging in Patients Undergoing Cancer Treatment.
Wengrofsky P; Feldman S
Curr Cardiol Rep; 2023 Jan; 25(1):1-8. PubMed ID: 36527535
[TBL] [Abstract][Full Text] [Related]
43. [Current recommendations for diagnostic echocardiography in cancer patients : Is echocardiography too late or too early?].
Kruck I
Herz; 2017 May; 42(3):262-270. PubMed ID: 28233035
[TBL] [Abstract][Full Text] [Related]
44. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study.
Jacob S; Pathak A; Franck D; Latorzeff I; Jimenez G; Fondard O; Lapeyre M; Colombier D; Bruguiere E; Lairez O; Fontenel B; Milliat F; Tamarat R; Broggio D; Derreumaux S; Ducassou M; Ferrières J; Laurier D; Benderitter M; Bernier MO
Radiat Oncol; 2016 Apr; 11():54. PubMed ID: 27056179
[TBL] [Abstract][Full Text] [Related]
45. Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction.
Ong DS; Scherrer-Crosbie M; Coelho-Filho O; Francis SA; Neilan TG
Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):487-97. PubMed ID: 24650314
[TBL] [Abstract][Full Text] [Related]
46. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.
Schmitz KH; Prosnitz RG; Schwartz AL; Carver JR
Cancer; 2012 Apr; 118(8 Suppl):2270-6. PubMed ID: 22488701
[TBL] [Abstract][Full Text] [Related]
47. Cardio-oncology for Pediatric and Adolescent/Young Adult Patients.
Tolani D; Wilcox J; Shyam S; Bansal N
Curr Treat Options Oncol; 2023 Aug; 24(8):1052-1070. PubMed ID: 37296365
[TBL] [Abstract][Full Text] [Related]
48. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
Lenneman CG; Sawyer DB
Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
[TBL] [Abstract][Full Text] [Related]
49. Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity.
Bottinor W; Chow EJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):251-258. PubMed ID: 36485088
[TBL] [Abstract][Full Text] [Related]
50. Prospective cardiac MRI for the analysis of biventricular function in children undergoing cancer treatments.
de Ville de Goyet M; Brichard B; Robert A; Renard L; Veyckemans F; Vanhoutte L; Moniotte S
Pediatr Blood Cancer; 2015 May; 62(5):867-74. PubMed ID: 25597617
[TBL] [Abstract][Full Text] [Related]
51. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
52. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
53. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
54. Cardiac imaging in cardiotoxicity: a focus on clinical practice.
Makavos G; Ikonomidis I; Palios J; Rigopoulos A; Katogiannis K; Parissis J; Paraskevaidis I; Noutsias M
Heart Fail Rev; 2021 Sep; 26(5):1175-1187. PubMed ID: 32306221
[TBL] [Abstract][Full Text] [Related]
55. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
56. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
[TBL] [Abstract][Full Text] [Related]
57. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.
Khouri MG; Klein MR; Velazquez EJ; Jones LW
Future Cardiol; 2015 Jul; 11(4):471-84. PubMed ID: 26235924
[TBL] [Abstract][Full Text] [Related]
58. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.
Kostakou PM; Kouris NT; Kostopoulos VS; Damaskos DS; Olympios CD
Heart Fail Rev; 2019 Jan; 24(1):91-100. PubMed ID: 30073443
[TBL] [Abstract][Full Text] [Related]
59. Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to "Omics" Technologies.
Madonna R
Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):576-582. PubMed ID: 28246019
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
